TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23226426
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy + Cetuximab or Panitumumab
Study: 23226426
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy + Cetuximab
Study: 23226426
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy + Anti-EGFR drugs
Study: 17432692
Drug: Qingjin Runfei
Normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingjie Shine Mastic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingjin Runfei Decoction (QRD) combined with hormone and antibiotic
Study: 17432692
Drug: Hormone and
Normalized name: Parathyroid hormone and/or parathyroid hormone derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone and antibiotic
Study: 15610365
Drug: Active omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active omega-3 supplemented group (daily tuna fish oil supplement and omega-3-rich margarines and cooking oils)
Study: 15610365
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo supplement with polyunsaturated margarines and cooking oils)
Study: 10845823
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate calcium concentration (HdCa; 1.75 mmol/L)
Study: 10845823
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate calcium concentration (LdCa; 1.25 mmol/L)
Study: 10845823
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from HdCa to LdCa treatment
Study: 10845823
Drug: Both LdCa
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both LdCa and HdCa treatment groups
Study: 9354201
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, metronidazole 400 mg t.d.s. for the first week)
Study: 9354201
Drug: Omeprazole dual
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole dual therapy (40 mg once daily, amoxycillin 1 g b.d. for 2 weeks, placebo during the first week)
Study: 9354201
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients treated analysis for omeprazole triple therapy
Study: 9354201
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients treated analysis for omeprazole dual therapy
Study: 9354201
Drug: Consultations, investigations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consultations, investigations, and prescriptions relating to upper gastrointestinal symptoms
Study: 3545686
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 to 20 mg per day)
Study: 3545686
Drug: Pindolol alone
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol alone or in combination with a diuretic
Study: 24413697
Drug: Post-study caffeine
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-study caffeine administration
Study: 19448528
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive Pills (OCPs)
Study: 18036290
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with low dose fentanyl (Group PF)
Study: 18036290
Drug: Midazolam combined
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam combined with low dose fentanyl (Group MF)
Study: 9734883
Drug: Portal-vein infusion
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal-vein infusion (PVI) of fluorouracil (500 mg/m2) plus heparin (5000 IU daily for 7 days)
Study: 9734883
Drug: Portal-vein infusion
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal-vein infusion (PVI) of fluorouracil
Study: 8111606
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (16 mg/day)
Study: 8111606
Drug: Albuterol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (800 micrograms/day)
Study: 26032655
Drug: Liraglutide (LIRA)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (LIRA) 1.2 mg QD s.c.
Study: 26032655
Drug: Roflumilast (ROF)
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast (ROF) 500 mcg QD
Study: 23609792
Drug: Fructose combined
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose combined with fat (0.5 g/kg body weight fructose, 1 g/kg OFTT cream as fat)
Study: 23609792
Drug: Fat only
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat only (1 g/kg OFTT cream)
Study: 23609792
Drug: Glucose (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (0.5 g/kg body weight)
Study: 23609792
Drug: Fructose (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (0.5 g/kg body weight)
Study: 21746729
Drug: Moderate-oxygen group
Normalized name: Corticosteroids, moderately potent (group II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-oxygen group (oxygen titration starting from 100%)
Study: 19166298
Drug: Purple carrot
Normalized name: Purple Carrot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple carrot juice containing 76 micromol (65 mg) of total anthocyanins
Study: 19166298
Drug: Purple carrot
Normalized name: Purple Carrot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple carrot juice containing 228 micromol (194 mg) of total anthocyanins
Study: 19166298
Drug: Purple carrot
Normalized name: Purple Carrot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple carrot juice containing 380 micromol (323 mg) of total anthocyanins
Study: 16700404
Drug: Liquid multi-vitamin/mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid multi-vitamin/mineral supplement
Study: 16146036
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment only
Study: 14559928
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing 150 mg DHEA, 300 mg androstenedione, 750 mg Tribulus terrestris, 625 mg chrysin, 300 mg indole‐3‐carbinol, and 540 mg saw palmetto
Study: 14559928
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing DHEA, androstenedione and herbal extracts
Study: 9256120
Drug: Extended triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended triple intrathecal therapy (TIT)
Study: 1554839
Drug: Ceftriaxone (≤2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (≤2 g IM daily for at least 2 weeks)
Study: 24237879
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.2 mg·kg(‐1))
Study: 24237879
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (1 μg·kg(‐1))
Study: 20038617
Drug: Amdoxovir (AMDX)
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 200 mg b.i.d.
Study: 20038617
Drug: Amdoxovir (AMDX)
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdoxovir (AMDX) at 500 mg b.i.d. + ZDV at 300 mg b.i.d.
Study: 20038617
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) at 200 mg b.i.d.
Study: 20038617
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) at 300 mg b.i.d.
Study: 20038617
Drug: Amdoxovir (AMDX)
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amdoxovir (AMDX) at 500 mg b.i.d. + placebo
Study: 16408674
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination timolol‐dorzolamide
Study: 12716811
Drug: Electronic reminder
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic reminder plus a letter summarizing the beneficial effects of antiplatelet drugs
Study: 7581058
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Loratadine daily for 3-4 days
Study: 7581058
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 30 mg Loratadine
Study: 7581058
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Loratadine for 5 days
Study: 6123332
Drug: Estazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (2 mg)
Study: 25713293
Drug: ACEI/ARB therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB therapy
Study: 26194691
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Oral contraceptives (OC)
Study: 23592752
Drug: 3.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g/d EPA + DHA supplementation
Study: 23592752
Drug: 0.85 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85 g/d EPA + DHA supplementation
Study: 15289960
Drug: UDCA (8-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (8-10 mg/kg per day)
Study: 8088691
Drug: nilvadipine 8
Normalized name: nilvadipine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nilvadipine 8 mg (mornings) and placebo (evenings)
Study: 8088691
Drug: slow‐release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow‐release nifedipine 20 mg b.i.d.
Study: 2654201
Drug: Computer-based instructional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based instructional system in pharmacokinetics
Study: 2654201
Drug: Conventional teaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional teaching in clinical pharmacokinetics
Study: 6104497
Drug: Flunitrazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.25 mg ml-1 i.v. (average dose 0.014 mg kg-1)
Study: 6104497
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg ml-1 i.v. (0.29 mg kg-1)
Study: 26844764
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum albumin levels (mean 3.5 ± 0.5 g/dL)
Study: 12944341
Drug: Aripiprazole, 30
Normalized name: Aripiprazole, 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole, 30 mg/day (reduced to 15 mg/day if needed for tolerability)
Study: 10870361
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of racemic ketamine
Study: 3519236
Drug: Disopyramide capsules
Normalized name: disopyramide Oral Capsule
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide capsules (600 mg per day, q.i.d.)
Study: 3519236
Drug: Disopyramide slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide slow release tablets (600 mg per day, b.i.d.)
Study: 28850429
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy or manual therapy
Study: 25239466
Drug: Nevirapine at
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine at 200 mg twice daily
Study: 25239466
Drug: Efavirenz at
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz at 600 mg daily
Study: 21712242
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg once daily
Study: 21712242
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg with atazanavir 300 mg/ritonavir 100 mg once daily
Study: 21712242
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg three times weekly with atazanavir/ritonavir
Study: 19584189
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol combined with 2.5 mg medroxyprogesterone
Study: 19584189
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d oral risedronate (Actonel)
Study: 7967425
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (IST) using anti-lymphocyte globulin (ALG), cyclosporin A (CSA), and G-CSF
Study: 7967425
Drug: Standardisation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardisation and improvement of supportive therapy
Study: 2890791
Drug: Betaxolol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.5% ophthalmic solution
Study: 28395753
Drug: Selamectin/sarolaner spot-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selamectin/sarolaner spot-on formulation (6.0 mg selamectin and 1.0 mg sarolaner per kg bodyweight)
Study: 28395753
Drug: Selamectin/sarolaner spot-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selamectin/sarolaner spot-on formulation
Study: 25792808
Drug: BP-C1 treatment
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP-C1 treatment (daily intramuscular injections for 32 days)
Study: 25792808
Drug: BP-C1 treatment
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP-C1 treatment
Study: 23327861
Drug: Olopatadine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 5 mg orally twice a day for 14 days
Study: 23327861
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg orally once a day for 14 days
Study: 21335259
Drug: Demographic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic and contextual variables (e.g., ethnicity, gender, marital status, education, smoking in the workplace, number of smokers in the social network, number of supportive others)
Study: 11723153
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of hydroxycobalamin for 5 months
Study: 9741608
Drug: Pre‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐ and postexercise rectal temperature
Study: 3132853
Drug: Standard 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 5% dextrose and electrolyte solutions
Study: 21679528
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (Tsang‐Erh‐San extract granules and Houttuynia extract powder) for 8 weeks
Study: 21679528
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 4 weeks
Study: 20175801
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg co-administered with halofantrine 500 mg
Study: 20175801
Drug: Halofantrine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 500 mg alone
Study: 11194517
Drug: Infusion warmer
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion warmer and standard O.R. draping with two layers of cotton drapes (Group 1)
Study: 11194517
Drug: Infusion warmer
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion warmer and reflecting disposable insulation (Thermadrape) (Group 2)
Study: 11194517
Drug: Infusion warmer
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion warmer and convective air warming with upper body blanket (Group 3)
Study: 11194517
Drug: Infusion warmer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion warmer, convective air warming and reflecting disposable insulation (Group 4)
Study: 28846877
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CII) of enoxaparin 40mg over 24h for three consecutive days
Study: 28846877
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus (SCB) administration of enoxaparin 40mg once daily
Study: 27308826
Drug: Tyloxapol 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyloxapol 1% (5 ml inhaled three times daily for 3 weeks)
Study: 27308826
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (5 ml inhaled three times daily for 3 weeks)
Study: 19349629
Drug: Pharmacotherapy supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy supplemented with up to 6 counseling calls (high‐intensity disease management)
Study: 19349629
Drug: Pharmacotherapy supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy supplemented with up to 2 counseling calls (moderate‐intensity disease management)
Study: 11386927
Drug: ramipril, 2.5
Normalized name: Ramipril, 2.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril, 2.5 to 10 mg/d
Study: 11386927
Drug: amlodipine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine, 5 to 10 mg/d
Study: 9731994
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks
Study: 9731994
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg BID for 4 weeks
Study: 9731994
Drug: CLR 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLR 500 mg TID for the first 2 weeks
Study: 7837160
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (no etidronate treatment)
Study: 3422694
Drug: Slow intravenous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intravenous infusion of epirubicin
Study: 3422694
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of epirubicin
Study: 29281033
Drug: Topiramate 200
Normalized name: topiramate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 200 mg/day and Aripiprazole 15 mg/day (combined)
Study: 25352640
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg three times daily for 2 weeks
Study: 25010608
Drug: Triple-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose albendazole
Study: 19876587
Drug: Camostat mesilate
Normalized name: Camostat mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesilate 200 mg three times daily for 2 weeks
Study: 18373286
Drug: C5: 2
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C5: 2 x 5-g doses of creatine
Study: 18373286
Drug: C10: 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: C10: 1 x 10-g dose of creatine
Study: 9847435
Drug: Levalbuterol 0.63
Normalized name: levalbuterol 0.63 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol 0.63 mg
Study: 9847435
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol 2.5 mg
Study: 11011341
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) adenosine boluses at a dose of 15 to 20 microgram in the right and 18 to 24 microgram in the left coronary artery.
Study: 11011341
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) adenosine administered as a continuous infusion at a rate of 140 microgram/kg per minute until steady state hyperemia was achieved.
Study: 8222668
Drug: 5 day
Normalized name: Fresh 5 Day Deodorant Pads
DrugBank: Aluminum chlorohydrate (DB11573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 day course of external beam radiation therapy followed by enucleation
Study: 27247914
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg oral 90 minutes before surgery
Study: 27247914
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg intravenous 90 seconds before intubation
Study: 23715582
Drug: Ridaforolimus 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 40 mg once per day for 5 days every week
Study: 20884464
Drug: Three prunes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three prunes (11.43g) soaked in water, consumed daily for 8 weeks
Study: 20884464
Drug: Six prunes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six prunes (23g) soaked in water, consumed daily for 8 weeks
Study: 20884464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group given a glass of water daily for 8 weeks
Study: 18447225
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation combined with target-controlled infusion (TCI)